Learning From Negative Clinical Trials in Pancreatic Cancer
January 26th 2017Philip A. Philip, MD, PhD, professor of oncology and pharmacology, Karmanos Cancer Institute, Wayne State University, discusses how researchers in the pancreatic cancer field can learn from recent negative clinical trials.
Watch
Tarextumab in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
January 23rd 2017Eileen M. O’Reilly, MD, discusses results of a randomized phase II trial of tarextumab in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic cancer.
Watch
Interim Results for Gastric Cancer Treatment With Ramucirumab Plus Pembrolizumab
January 21st 2017Ian Chau, MD, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.
Watch
The Impact of Age, Comorbidity on Postoperative Outcomes in Esophageal and Gastric Cancer
January 20th 2017Christophe Mariette, MD, PhD, surgical oncologist and professor of surgery, University Hospital of Lille in France, discusses a nationwide study investigating the impact of age and comorbidities on postoperative mortality after esophageal and gastric cancer surgery.
Watch
An Overview of EarlyR Gene Signature in the BIG-198 Trial for Breast Cancer
January 14th 2017Steven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the Breast International Group 1-98 study.
Watch
An Overview of the GeparSepto Trial in Luminal, Triple-Negative, and HER2+ Breast Cancer
January 5th 2017Sibylle Loibl, MD, PhD, co-chair of the German Breast Group and associate professor at the University of Frankfurt, discusses the most recent subanalysis of the GeparSepto trial in luminal, triple-negative, and HER2+ breast cancer.
Watch
A Study Investigating Pembrolizumab in Combination With Eribulin in TNBC
January 3rd 2017Sara Tolaney, MD, MPH, associate clinical research director of Breast Oncology at the Dana-Farber Cancer Institute in Boston, discusses a clinical trial investigating pembrolizumab in combination with eribulin in triple-negative breast cancer.
Watch